FDA and CPMP rulings on subgroup analyses

Area of Science:

• Clinical trial methodology
• Regulatory science
• Pharmaceutical medicine

Background:

• Subgroup analyses in clinical trials present interpretation challenges.
• Guidelines from the US Food and Drug Administration (FDA) and EU Committee for Proprietary Medicinal Products (CPMP) address subgroup analyses.
• The role of subgroup analyses in trial interpretation is a contentious issue.

Purpose of the Study:

• To discuss the interpretation and impact of subgroup analyses in clinical trial reports.
• To highlight the regulatory perspectives from the FDA and CPMP on subgroup analyses.
• To examine how subgroup analyses can influence drug approval and product labeling.

Main Methods:

• Review of established guidelines from regulatory authorities (FDA, CPMP).
• Discussion of planned versus exploratory subgroup and interaction analyses.
• Case examples from heart failure trials (Val-HeFT, MERIT-HF) illustrating regulatory issues.

Main Results:

• Subgroup analyses should be pre-specified in trial protocols.
• Exploratory subgroup analyses require cautious interpretation.
• Drug approval is based on overall trial results, not subgroup analyses, though they can influence labeling.

Conclusions:

• Subgroup analyses, whether planned or exploratory, play a role in understanding treatment effects.
• Regulatory decisions on market approval are based on overall trial efficacy and safety.
• Subgroup findings can impact product labeling and require careful consideration by regulatory bodies.